1,221,596 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Purchased by Jupiter Topco LLC

Jupiter Topco LLC acquired a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,221,596 shares of the biotechnology company’s stock, valued at approximately $99,623,000. Jupiter Topco LLC owned 0.87% of Arrowhead Pharmaceuticals at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in ARWR. Tsfg LLC purchased a new position in shares of Arrowhead Pharmaceuticals during the 4th quarter valued at approximately $25,000. Optiver Holding B.V. lifted its holdings in Arrowhead Pharmaceuticals by 83.8% during the first quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 186 shares in the last quarter. Versant Capital Management Inc lifted its holdings in Arrowhead Pharmaceuticals by 285.1% during the second quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 248 shares in the last quarter. Carolina Wealth Advisors LLC grew its position in shares of Arrowhead Pharmaceuticals by 80.6% in the second quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 154 shares during the period. Finally, iSAM Funds UK Ltd purchased a new stake in shares of Arrowhead Pharmaceuticals during the third quarter worth about $29,000. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Michael S. Perry sold 11,600 shares of Arrowhead Pharmaceuticals stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total transaction of $1,012,680.00. Following the transaction, the director owned 111,459 shares in the company, valued at $9,730,370.70. The trade was a 9.43% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Adeoye Y. Olukotun sold 2,000 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total transaction of $173,920.00. Following the transaction, the director directly owned 31,600 shares in the company, valued at approximately $2,747,936. The trade was a 5.95% decrease in their position. The SEC filing for this sale provides additional information. 3.60% of the stock is owned by company insiders.

Arrowhead Pharmaceuticals Price Performance

ARWR stock opened at $89.12 on Thursday. The company has a debt-to-equity ratio of 1.77, a current ratio of 5.90 and a quick ratio of 5.90. The business has a 50 day simple moving average of $83.44 and a 200-day simple moving average of $73.29. The firm has a market capitalization of $12.55 billion, a PE ratio of -39.61 and a beta of 1.27. Arrowhead Pharmaceuticals, Inc. has a 1 year low of $21.06 and a 1 year high of $95.49.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported ($1.36) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). The company had revenue of $75.25 million for the quarter, compared to analysts’ expectations of $44.17 million. Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%.The business’s quarterly revenue was up 171.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.26) EPS. Equities research analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -3.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Piper Sandler restated an “overweight” rating and set a $126.00 price target (up from $110.00) on shares of Arrowhead Pharmaceuticals in a research report on Thursday, July 23rd. Sanford C. Bernstein raised their target price on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the company a “market perform” rating in a research report on Wednesday, May 13th. Royal Bank Of Canada boosted their price target on Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the stock an “outperform” rating in a research report on Friday, May 8th. HC Wainwright raised their price objective on Arrowhead Pharmaceuticals from $115.00 to $120.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. Nine research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $97.33.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.